As of 2025-10-19, the Intrinsic Value of Haemonetics Corp (HAE) is 79.90 USD. This HAE valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 50.26 USD, the upside of Haemonetics Corp is 59.00%.
The range of the Intrinsic Value is 50.49 - 162.43 USD
Based on its market price of 50.26 USD and our intrinsic valuation, Haemonetics Corp (HAE) is undervalued by 59.00%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 50.49 - 162.43 | 79.90 | 59.0% |
| DCF (Growth 10y) | 67.73 - 195.99 | 101.64 | 102.2% |
| DCF (EBITDA 5y) | 50.67 - 68.21 | 58.17 | 15.7% |
| DCF (EBITDA 10y) | 67.65 - 93.11 | 78.61 | 56.4% |
| Fair Value | 84.75 - 84.75 | 84.75 | 68.63% |
| P/E | 51.53 - 119.33 | 81.85 | 62.9% |
| EV/EBITDA | 42.02 - 63.63 | 51.10 | 1.7% |
| EPV | 38.98 - 55.43 | 47.20 | -6.1% |
| DDM - Stable | 29.85 - 86.54 | 58.19 | 15.8% |
| DDM - Multi | 42.56 - 97.31 | 59.38 | 18.2% |
| Market Cap (mil) | 2,421.53 |
| Beta | 0.63 |
| Outstanding shares (mil) | 48.18 |
| Enterprise Value (mil) | 3,353.41 |
| Market risk premium | 4.60% |
| Cost of Equity | 8.74% |
| Cost of Debt | 4.25% |
| WACC | 6.90% |